Dr Sharon Lynn Space, MD in Ashford, CT - Pediatrics

Dr Sharon Lynn Space, MD is a Pediatrics - Pediatric Hematology-oncology physician based in Ashford, Connecticut. Dr Sharon Lynn Space is licensed to practice in Connecticut (license number 043362) and her current practice location is 565 Ashford Center Rd, Ashford, Connecticut. She can be reached at her office (for appointments etc.) via phone at (860) 429-3444.

NPI number for Dr Sharon Lynn Space is 1134375058 and her current mailing address is 565 Ashford Center Rd, Ashford, Connecticut. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1134375058.

Contact Information

	Dr Sharon Lynn Space, MD
	565 Ashford Center Rd, Ashford, CT 06278-1720
	(860) 429-3444
	(860) 429-1586

Physician's Profile

Full Name	Dr Sharon Lynn Space
Gender	Female
Speciality	Pediatrics - Pediatric Hematology-oncology
Location	565 Ashford Center Rd, Ashford, Connecticut
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1134375058
Provider Enumeration Date: 08/12/2008
Last Update Date: 08/12/2008

Medical Identifiers

Medical identifiers for Dr Sharon Lynn Space such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1134375058	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
2080P0207X	Pediatrics - Pediatric Hematology-oncology	043362 (Connecticut)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Sharon Lynn Space is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Sharon Lynn Space, MD 565 Ashford Center Rd, Ashford, CT 06278-1720 Ph: (860) 429-3444	Dr Sharon Lynn Space, MD 565 Ashford Center Rd, Ashford, CT 06278-1720 Ph: (860) 429-3444

News Archive

Fero Industries to complete acquisition of Pyro Pharmaceuticals by November 30, 2009

Fero Industries, Inc. is pleased to provide certain disclosures relating to the ten pending patent applications of Pyro Pharmaceuticals, Inc. As previously announced, the Company has initiated the process of acquiring Pyro Pharmaceuticals, Inc. through an exchange of Pyro's capital stock for shares of the Company's common stock, with Fero remaining as the parent entity and Pyro as a subsidiary. The acquisition of Pyro is expected to close by November 30, 2009.

Health overhaul will boost coverage for millions, but leaves gaps, too

The health legislation President Barack Obama signed into law would extend insurance to 32 million Americans by 2019, but that still leaves out 23 million, The Christian Science Monitor reports.

State roundup: Legislatures tackle health budget gaps, worker pay

With the national economy picking up and the housing market improving, states are poised in 2013 to finally rebound from the recession's lingering revenue crunch. But continued budget delays in Washington may dampen that prospect.

Bioactive lipid LPA mediates fibrogenesis in bleomycin mouse model of scleroderma

Amira Pharmaceuticals, Inc. announced today that their collaborators, Andrew Tager, M.D. and Flavia V. Castelino, M.D. of Massachusetts General Hospital, Harvard Medical School, will present a preclinical proof-of-concept study which demonstrates that the bioactive lipid lysophosphatidic acid (LPA), through its high affinity LPA1 receptor, is an important mediator of fibrogenesis in the bleomycin mouse model of scleroderma. Data will be presented as part of a poster session for the 1st Systemic Sclerosis World Congress to be held in Florence, Italy, February 11 to 13, 2010.

Finding targets prostate patients who would not benefit from cancer-detecting biopsy

UC Irvine Health urologists and health policy experts report in a new study that two written assessments that identify existing comorbidities - the patient-reported Total Illness Burden Index for Prostate Cancer (TIBI-Cap) and the physician-reported Charlson Comorbidity Index - can successfully target prostate patients who would not benefit from biopsy to discover possible cancer.

Dr Sharon Lynn Space, MD - Pediatrics in Ashford, CT